Erasca to Present at the Bank of America Securities 2022 Healthcare Conference

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Bank of America Securities 2022 Healthcare Conference. CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a virtual fireside chat on May 10, 2022, at 1:20 p.m. PT. They will also hold one-on-one investor meetings. A live webcast will be available on the Bank of America website, with an archived replay accessible until August 10, 2022. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer.

News Market Reaction – ERAS

-3.92%

-3.92% Session move

In the trading session that priced this news, ERAS declined 3.92%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2022 Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 1:20 p.m. Pacific Time on Tuesday, May 10, 2022, in Las Vegas, Nevada. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at bofa/webcasts/. An archived replay of the event will be available until August 10, 2022, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

What is the date and time of Erasca's participation in the Bank of America Healthcare Conference?

Erasca will participate in the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 1:20 p.m. Pacific Time.

Who from Erasca will represent the company at the Healthcare Conference?

Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will represent Erasca at the conference.

Where can I access the live webcast of Erasca's presentation?

The live webcast of Erasca's presentation can be accessed on the Bank of America website.

How long will the archived replay of Erasca's presentation be available?

The archived replay of Erasca's presentation will be available until August 10, 2022.

What is Erasca's focus in the oncology field?

Erasca is focused on discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers.